Skip to content

Percutaneous Transhepatic Variceal Embolization versus Endoscopic Injections with Histoacryl for the treatment of gastric fundus varices: A Randomized Controlled Trial

Percutaneous Transhepatic Variceal Embolization versus Endoscopic Injections with Histoacryl for the treatment of gastric fundus varices: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000251
Enrollment
Unknown
Registered
2008-12-22
Start date
2003-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Control group:Patients has gastroscopy to investigate the degree of gastric fundus varices
Histoacryl blue injection was performed using an Olympus electronic gastroscope and a disposable injection needle. Each shot contained 0.5ml Histoacryl and 0.5ml Lipiodol. Last the needles were rinsed
Experimental group:The included patients was performed PTVE by venipuncture, intubation tube, visualization, histoacryl was then injected continuously until all the gastric fundus varices and opacifie

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
47 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Cirrhotic patients with acute or recent (within 3 months) gastric variceal hemorrhage; 2. Cirrhotic patients was confirmed with the clinical and image data; 3. The degree of gastric varices was confirmed by gastroendoscopy in these patients; 4. Computerized tomography (CT) portal venography was performed for detection of variceal afferent veins before operation; 5. Giving the consent to complete preoperative check and postoperative recheck.

Exclusion criteria

Exclusion criteria: 1. Association with the contraindication such as esophageal stenosis for gastroscopy or has grave esophagitis; 2. Had previous endoscopic, surgical treatment or transjugular intrahepatic portal systemic shunt for gastroesophageal variceal bleeding; 3. Grave hypertension, coronary heart disease, or impaired function of cardiorespiratory. 4. Association with hepatocellular carcinoma or other malignancy; 5. Complete obstruction of the portal vein due to thrombosis; 6. Encephalopathy greater than stage II; severe jaundice with serum bilirubin more than 100 mg L-1; 7. Presence of hepatorenal syndrome or chronic renal insufficiency; 8. Obvious hemorrhagic tendency, PT>25s; 9. The portal vein was failure to venous cannula with kinds of cause; 10. Inability or refusal to give the consent to complete preoperative check and postoperative recheck.

Design outcomes

Primary

MeasureTime frame
UGI rebleeding;Computerized tomography (CT) scanning and 3D recon;survival rate;Arrest of acute bleeding;Gastric Fundus Varices eradication and relaps;

Secondary

MeasureTime frame
The improving of clinical symptom;Liver functional assessment;quality of life;Complication;

Countries

China

Contacts

Public ContactZhang Chunqing
zhchqing@medmail.com.cn+86 0 13583188661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026